Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.66 |
| ▸ | MTOR | P42345 | 2/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10594359 | 0.86 | GAA (0.73) | LMNAGAAMEN1KMT2ATRPV1 | |
| SCHEMBL13234944 | 0.82 | CA12 (0.89) | LMNAGAAMAPK1TRPV1CA12 | |
| SCHEMBL27979652 | 0.81 | CA12 (0.71) | LMNAGAAMAPK1MEN1KMT2A | |
| SCHEMBL32189 | 0.80 | MTOR (1.00) | PIK3CAMTORPIK3CG | |
| SCHEMBL32703 | 0.80 | MTOR (0.74) | PIK3CAMTORPIK3CG | |
| SCHEMBL32482 | 0.78 | MTOR (0.83) | PIK3CAMTORPIK3CG | |
| SCHEMBL13234938 | 0.78 | CA12 (0.77) | LMNAGAAMAPK1MEN1HTT | |
| SCHEMBL32984 | 0.77 | MTOR (0.77) | PIK3CAMTORPIK3CG | |
| SCHEMBL11290550 | 0.76 | LMNA (0.57) | LMNAGAAMAPK1MEN1KMT2A | |
| SCHEMBL32635 | 0.76 | PIK3CA (0.69) | PIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076973-A1 | Compounds and methods for treating diseases caused by SARS-CoV-2 and other coronaviruses | Viradem, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2024151953-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES CAUSED BY SARS-COV-2 AND OTHER CORONAVIRUSES | VIRADEM INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076973-A1 | Compounds and methods for treating diseases caused by SARS-CoV-2 and other coronaviruses | ACE2, ACE, SARS1 | LMNA 1163/4885GAA 2875/4885MAPK1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.